China Approves Two Innovative Cancer Drugs and Puts Nine Under Review in July
Minhua Chu · 09/01/2021
China’s pursuit of innovative oncology drugs has kept Chinese regulators busy in July, as they granted the first marketing approvals to two foreign drugs and accepted NDAs for nine more new ones.
READ MORE
China Market Approvals Surge in June
Minhua Chu · 07/23/2021
China Market Approval Tracker: Jun 2021
READ MORE
China Market Approval Tracker: May 2021
Minhua Chu · 07/19/2021
The NMPA Grants Three Orphan Drugs Market Approval.
READ MORE
China Market Approval Tracker: Apr 2021
Minhua Chu · 07/19/2021
NMPA Expands Three PD-1(L1) Antibodies to Key Patient Populations in China.
READ MORE
China Market Approval Tracker: Mar 2021
Minhua Chu · 07/19/2021
New Cancer & SLE Drugs Gain Market Approval in China
READ MORE
China Market Approval Tracker: Feb 2021
Minhua Chu · 07/19/2021
Six NMEs Get Market Approval in China.
READ MORE
China Market Approval Tracker: Jan 2021
Minhua Chu · 07/19/2021
Takeda、Beigene、Antengene
READ MORE
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement